Akamai Technologies has spent the week unwinding a slice of its extraordinary post-earnings rally, dropping 6.3% on Tuesday alone to close at $141.34 — and options traders are now more defensive than they have been in months.
The clearest shift this week is in the options market. The put/call ratio jumped to 0.58, well above its 20-day average of 0.49 and running at roughly 1.5 standard deviations above the mean. That is the highest defensive reading since April, and a notable reversal from earlier in the week when the PCR printed a 52-week low of 0.34. In short: the same market that was aggressively positioned for upside on Monday had rotated into protective puts by Tuesday's close. The week's price action — down 5.5% on balance — appears to have prompted a reassessment.
Short interest tells a more stable story. The short base ticked up 1.4% over the week to 11.2% of the free float, a modest rebuild after the heavy covering wave that followed the May 7 earnings explosion. That places short interest above where it was last week but materially below the mid-April peak of around 12.6%. Borrow conditions remain unthreatening: cost to borrow has fallen almost 20% over the past month to just 0.41% annualised, a multi-month low. Availability is wide at 449%, comfortably above the 52-week floor of 388% — meaning there is ample supply in the lending pool relative to current short demand. The short base is rebuilding slowly and on conviction, not because of any squeeze or forced covering dynamic.
The Street has moved decisively bullish in the past two weeks, but with a split message on valuation. After the Q1 beat, Bank of America upgraded to Buy and lifted its target from $130 to $175. Morgan Stanley's Keith Weiss raised to $165 while keeping Overweight. Targets from Scotiabank, Guggenheim, and Keybanc were raised aggressively, with Keybanc moving to $195 — the most optimistic on the Street. The consensus mean target now stands at $157.16, implying roughly 11% upside from current levels. The bull case centres on the $1.8 billion AI inference deal and Akamai's emerging position in GPU-driven cloud infrastructure. Bears counter that last quarter's results still missed expectations, capex is rising, and the large deals may already be priced in. EV/EBITDA has compressed slightly to 13.1x over the past month as the stock pulled back, but the PE multiple at 20.6x has expanded roughly 7 points over 30 days — a sign the stock re-rated sharply on the earnings catalyst and is now digesting that move.
Capital Research and Management Company initiated or significantly rebuilt a position in the stock as of April 30, reporting 6.9 million shares with a change figure suggesting a fresh or near-full entry. BNY Asset Management added nearly 500,000 shares in the same reporting window. Point72 trimmed by around 496,000 shares as of March 31 — a hedge fund reducing exposure into the April weakness that preceded the earnings surge. The institutional picture is broadly constructive, with the largest passive holders — Vanguard at 12.6% and BlackRock at 7.2% — both adding modestly.
Peer FSLY fell 14% on the week, a sharper move than AKAM's 5.5% decline, while DOCN gave back 3.7%. The relative outperformance of AKAM against its closest CDN and edge-infrastructure peers suggests the stock is holding its post-earnings premium even through the current giveback. The next scheduled earnings event is August 4 — until then, the evolving sizing of the AI inference pipeline and any further commentary on the $1.8 billion deal capacity are the variables most worth tracking.
See the live data behind this article on ORTEX.
Open AKAM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
